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A B S T R A C T
Purpose
To compare pre-agreed health-related quality of life (HRQOL) domains in patients with esophageal or
junctional cancer who received neoadjuvant chemoradiotherapy (nCRT) followed by surgery or
surgery alone. Secondary aims were to examine the effect of nCRT on HRQOL before surgery and
the effect of surgery on HRQOL.
Patients and Methods
Patients were randomly assigned to nCRT (carboplatin plus paclitaxel with concurrent 41.4-Gy
radiotherapy) followed by surgery or surgery alone. HRQOL was measured using the European
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 (QLQ-
C30) and –Oesophageal Cancer Module (QLQ-OES24) questionnaires pretreatment and at 3, 6, 9,
and 12months postoperatively. The nCRT group also received preoperative questionnaires. Physical
functioning (PF; QLQ-C30) and eating problems (EA; QLQ-OES24) were chosen as predeﬁned
primary end points. Predeﬁned secondary end points were global QOL (GQOL; QLQ-C30), fatigue
(FA; QLQ-C30), and emotional problems (EM; QLQ-OES24).
Results
A total of 363 patients were analyzed. No statistically signiﬁcant differences in postoperative
HRQOL were found between treatment groups. In the nCRT group, PF, EA, GQOL, FA, and EM
scores deteriorated 1week after nCRT (Cohen’s d:20.93, P, .001; 0.47, P, .001;20.84, P, .001;
1.45, P , .001; and 0.32, P = .001, respectively). In both treatment groups, all end points declined
3months postoperatively compared with baseline (Cohen’s d:21.00, 0.33,20.47,20.34, and 0.33,
respectively; all P, .001), followed by a continuous gradual improvement. EA, GQOL, and EMwere
restored to baseline levels during follow-up, whereas PF and FA remained impaired 1 year post-
operatively (Cohen’s d: 0.52 and 20.53, respectively; both P , .001).
Conclusion
Although HRQOL declined during nCRT, no effect of nCRT was apparent on postoperative HRQOL
compared with surgery alone. In addition to the improvement in survival, these ﬁndings support the
view that nCRT according to the Chemoradiotherapy for Esophageal Cancer Followed by Surgery
Study–regimen can be regarded as a standard of care.
J Clin Oncol 36:268-275. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Esophageal cancer is characterized by high re-
currence rates and poor 5-year survival after pri-
mary surgical resection.1 To improve the radicality
of surgery and long-term survival, many trials on
the added value of neoadjuvant therapy have been
undertaken.2-8
One of the largest and most recent trials is the
Chemoradiotherapy for Esophageal Cancer Fol-
lowed by Surgery Study (CROSS). The randomized
CROSS trial compared carboplatin plus paclitaxel–
based neoadjuvant concurrent chemoradiotherapy
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(nCRT) regimen plus surgery with surgery alone in patients with
esophageal or esophagogastric junctional cancer from eight centers in
the Netherlands. Long-term results showed a statistically signiﬁcant
and clinically relevant increase in survival for both squamous cell and
adenocarcinoma subtypes, with acceptable toxicity.9,10 On the basis of
these results, the CROSS regimen is now standard treatment in many
countries.
The enhanced emphasis on health-related quality of life
(HRQOL) and other patient-reported outcome measures assumes
a more prominent role for these factors as end points in clini-
cal cancer trials.11 An esophagectomy is a major operation with
substantial morbidity and mortality and may have a profound
effect on patients’ QOL.12-14 However, in the ﬁeld of esophageal
cancer, only limited high-quality data on HRQOL are available. So
far, HRQOL data have been reported in two randomized esophageal
cancer trials, which compared transthoracic versus transhiatal
esophagectomy in patients who underwent primary surgery without
neoadjuvant therapy and primary surgery versus deﬁnitive CRT.15,16
Results from randomized trials in patients with esophageal cancer
investigating the effect of combined neoadjuvant therapy and sur-
gery on HRQOL have not yet been published. The available evidence
comes from two small observational studies. Both studies suggested
that the addition of nCRT to surgery had no inﬂuence on postoperative
HRQOL, but they were likely inﬂuenced by selection bias and
lacked statistical power.17,18
The primary aim of this substudy of the CROSS trial, with
HRQOL as a secondary end point, was to compare HRQOL in
patients with esophageal or junctional cancer who received nCRT
plus surgery or surgery alone. Furthermore, the effect of nCRTon
HRQOL before surgery and the effect of surgery on HRQOL were
examined over time. It was hypothesized that nCRT impairs
HRQOL before surgery but does not affect postoperative recovery
in terms of HRQOL.
PATIENTS AND METHODS
Details of this randomized trial have been reported previously and are
summarized in the Appendix Trial Design (online only).9,10,19
HRQOL Measurement
The self-report questionnaires were mailed after random assignment
and 3, 6, 9, and 12 months postoperatively. Postoperative HRQOL was
compared between both groups using date of surgery as reference point.
Patients who were randomly assigned to the nCRT group also received
questionnaires 1 week after nCRT (ie, 3 to 5 weeks before surgery).
Cancer-speciﬁc HRQOL was measured with the European Organi-
sation for Research and Treatment of Cancer (EORTC) Quality of Life
Questionnaire–Core 30 (QLQ-C30), a validated self-report questionnaire
for patients with cancer.20 Tumor-speciﬁc HRQOL was measured by the
EORTC QLQ–Oesophageal Cancer Module (QLQ-OES24), because the
currently used derivative QLQ-OES18 was not yet available.21
End points were predeﬁned by consensus discussion with expe-
rienced upper-GI surgical oncologists, medical oncologists, and nurse
practitioners before analysis of the data. End points were selected based on
clinical relevance and hypothesized association with nCRT. This led to the
primary end points of physical functioning (PF; QLQ-C30) and eating
problems (EA; QLQ-OES24). Secondary end points were deﬁned as global
QOL (GQOL; QLQ-C30), fatigue (FA; QLQ-C30), and emotional prob-
lems (EM; QLQ-OES24).
Statistical Analysis
Data were analyzed on an intention-to-treat basis, with comparison
of HRQOL as primary objective. Pretreatment characteristics were
compared using the Mann-Whitney or Student’s t test for continuous
variables and the x2 or Fisher’s exact test for categorical data.
Questionnaire scores were computed according to EORTC guide-
lines.22 Baseline HRQOL scores were compared using the Student’s t test.
Differential effects over time between treatment groups and longitudinal
comparison of the baseline scores and scores from follow-up measure-
ments (3, 6, 9, and 12 months postoperatively) were performed using
mixed modeling. If there were no statistically signiﬁcant differences over
time between both groups, baseline scores and scores from the post-
operative measurements of both groups were combined to analyze lon-
gitudinal HRQOL. Use of mixed modeling enabled the analysis of all data,
because it allowed for inclusion of questionnaire scores from patients with
different numbers of completed measurements.23 Therefore, the statistical
analyses included data from patients who were unable to complete the
questionnaires on one or more occasions and from those who dropped out
during the trial. Mean differences over time and differential effects over
time between treatment groups were described for statistically signiﬁcant
outcomes. Cohen’s d (CD) effect sizes were calculated to give an indication
of the clinical relevance of effects and to enable standardized comparison
between results from different outcome variables. CD effect sizes were
derived from the beta estimates in the mixed modeling procedure through
standardization of both outcome and predictor variables. CD values of 0.2,
0.5, and 0.8 indicate small, medium, and large effects, respectively.24
Values $ 0.5 were considered clinically relevant.25 In a separate analy-
sis, recurrence of disease and death in the subsequent time period were
included as control variables, which enabled the evaluation of possible
effect of recurrence of disease and death on the trajectory of HRQOL
scores. Recurrence of disease was deﬁned as the earliest occurrence of
disease progression resulting in irresectability, locoregional recurrence
(after completion of therapy), or distant dissemination (before, during, or
after treatment). To correct for multiple testing, statistical signiﬁcance was
set at P , .01 (the main analyses included ﬁve comparisons, and thus,
a Bonferroni correction of .05/5 was applied), except for baseline com-
parisons. For those latter analyses, P , .05 was considered signiﬁcant. All
reported P values are two sided. Statistical analysis was performed using
Statistical Package for the Social Sciences software, version 21.0 (SPSS,
Chicago, IL).
RESULTS
Of the 368 randomly assigned patients, 363 were included in the
HRQOL analysis. Two withdrew consent, two were enrolled in the
trial before the HRQOL study started, and one center (which
included one patient) did not participate in the HRQOL study
(Fig 1). There were no clinically relevant differences in pre-
treatment characteristics between groups (Table 1). Because of an
administrative error, 89 patients did not receive baseline ques-
tionnaires (nCRT group, n = 58; surgery-alone group, n = 31).
These patients were not excluded, because their baseline char-
acteristics did not differ signiﬁcantly from the study population
(data not shown), and follow-up questionnaires were correctly
completed.
Overall response rates at the different measurement points
were 54% to 76% and were lower in the surgery-alone group than
in the nCRT group (Table 2). At each measurement point, pre-
treatment characteristics (age, sex, tumor location, cT stage, cN
stage, and WHO performance status) of patients who completed
the questionnaires were not statistically different between the two
groups (data not shown). In the nCRT group, the median time to
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surgery calculated from the day of last radiation treatment was
46 days (interquartile range, 40 to 55 days). Mean scores of
HRQOL domains that were not predeﬁned end points are listed in
Table 3.
Predefined Primary End Points
PF. As shown in Figure 2A, baseline PF levels and all changes
over time were comparable between groups (P = .60 and P = .18,
respectively). PF declined at 3months postoperatively (218; P, .001;
CD, 21.00; 95% CI, 21.14 to 20.86) and improved from 3 to
6 months postoperatively (+5; P , .001; CD, 0.30; 95% CI, 0.18 to
0.41). From then, the improvement was no longer statistically sig-
niﬁcant (9 v 6 months, P = .07; 12 v 9 months, P = .27), and baseline
levels were not reached during follow-up (28; P, .001; CD,20.53;
95% CI, 20.67 to 20.39). In the nCRT group, PF declined 1 week
after nCRT (217; P , .001; CD, 20.93; 95% CI, 21.12 to 20.74).
EA. As shown in Figure 2B, no statistically signiﬁcant differences
in EA were found at baseline (P = .20), and changes over time were
comparable between groups (P = .45). Three months postoperatively,
EA had worsened in both groups (+8; P , .001; CD, 0.32; 95% CI,
0.15 to 0.50) and thereafter improved from 3 to 6 months (29;
P , .001; CD, 20.32; 95% CI, 20.44 to 20.20) and from 6 to
9 months (+5; P = .001; CD, 20.22; 95% CI, 20.34 to 20.09). In
both groups, 6 months postoperatively, EA levels returned to
baseline (P = .98), and no further improvement was found after
12months of follow-up compared with baseline levels (P= .01). The
nCRT group reported a deterioration in EA 1 week after completion
of nCRT (+12; P = .001; CD, 0.47; 95% CI, 0.21 to 0.72).
Predefined Secondary End Points
GQOL. As shown in Figure 2C, baseline GQOL scores and
all changes in GQOL over time were comparable between groups
(P = .53 and P = .76, respectively). GQOL scores signiﬁcantly de-
clined 3 months postoperatively (210; P = .002; CD, 20.47; 95%
CI, 20.62 to 20.31), improved between 3 and 6 months post-
operatively (+4; P = .001; CD, 0.24; 95% CI, 0.10 to 0.37), reached
baseline levels 9 months postoperatively (P = .31), and stabilized
subsequently (P = .34). Compared with baseline, patients in the
nCRT group reported signiﬁcantly worse GQOL 1 week after
nCRT (217; P , .001; CD, 20.84; 95% CI, 21.08 to 20.60).
FA. As shown in Figure 2D, baseline FA levels were com-
parable between groups (P = .42), and there were no statistically
signiﬁcant differences in changes over time (P = .30). Post-
operatively, FA levels worsened (+24; P , .001; CD, 1.01; 95% CI,
0.86 to 1.16) but subsequently improved in the periods from 3 to
6 months (28; P , .001; CD, 20.34; 95% CI, 20.46 to 20.22).
Thereafter, FA levels remained stable from 6 to 9 months (P = .04)
and from 9 to 12 months (P = .58) but did not return to baseline
levels (+10; P, .001; CD, 0.52; 95% CI, 0.38 to 0.65). In the nCRT
group, a signiﬁcant deterioration was reported 1 week after nCRT
(+34; P , .001; CD, 1.45; 95% CI, 1.23 to 1.66).
EM. As shown in Figure 2E, baseline EM scores were com-
parable between groups (P = .26), and both groups reported
comparable changes over time (P = .75). Three months post-
operatively, EM worsened (+8; P, .001; CD, 0.33; 95% CI, 0.18 to
0.49) but improved from 3 to 6 months (26; P, .001; CD,20.26;
95% CI, 20.40 to 20.13) and from 6 to 9 months (25; P = .003;
CD, 20.22; 95% CI, 20.36 to 20.08) postoperatively and stabi-
lized thereafter (9 to 12 months, P = .74). Baseline levels were
reached at 6 months (P = .39) and stabilized thereafter (P = .05).
Patients in the nCRT group reported a deterioration in EM 1 week
after nCRT (+9; P = .001; CD, 0.32; 95% CI, 0.14 to 0.50).
Results of the model including randomized grouping for
longitudinal effects are shown in Appendix Tables A1 to A5
(online only).
Assessed for esophageal or junctional cancer
(N = 873)
Enrolled and randomly assigned 
(n = 368)
Excluded
(n = 469)
Assigned to neoadjuvant chemoradiotherapy
(n = 180)
Assigned to surgery alone
(n = 188)
Assigned to neoadjuvant chemoradiotherapy
(n = 177)
Assigned to surgery alone
(n = 186)
Withdrew consent (n = 2)
(n = 1)   Included before HRQOL
    study start 
Center did not participate            (n = 1) 
   in HRQOL study         
   Included before HRQOL            (n = 1) 
     study start 
Fig 1. CONSORT diagram.HRQOL, health-
related quality of life.
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Influence of Recurrence of Disease and Death
Inclusion of recurrence of disease and death as control variables
did not inﬂuence the overall trends in HRQOL trajectories (data not
shown). However, the deterioration and restoration of primary and
secondary end points during follow-up were worse for patients who
developed recurrent disease and for patients who died in the subsequent
time period (data not shown). Patients in the surgery-alone group who
died during follow-up showed themost severe deteriorations, especially
in the 6- and 9-month follow-up measures.
Influence of Missing Baseline Questionnaires
Availability of a completed baseline questionnaire was
included as control variable. Inclusion of this variable did not
inﬂuence the described overall trends in HRQOL trajectories
(data not shown).
DISCUSSION
This randomized trial did not show statistically signiﬁcant dif-
ferences in postoperative HRQOL in patients with esophageal or
junctional cancer treated with a multimodality regimen based on
carboplatin plus paclitaxel with 41.4 Gy of concurrent radiotherapy
plus surgery, compared with patients who underwent surgery
alone. Patients in the nCRT group experienced deterioration in all
HRQOL end points immediately after completion of nCRT, but
this did not affect recovery during the ﬁrst postoperative year in
terms of HRQOL.
In both treatment groups, all primary and secondary HRQOL
end points declined postoperatively, but most were restored to
pretreatment levels within 1 year postoperatively. GQOL, EA, and
EM reached baseline levels 6 months (GQOL and EA) and
9 months postoperatively (EM) and stabilized from then. However,
PF and FA levels were not restored to pretreatment levels during
the ﬁrst year of follow-up, and corresponding effect sizes were
clinically relevant (CD,20.53 and 0.52, respectively). The scores of
these domains stabilized 6 and 9 months postoperatively, which
suggests that further spontaneous improvement to be unlikely.
This study is the ﬁrst clinical trial and the largest available
analysis to our knowledge comparing HRQOL in patients with
esophageal cancer who underwent neoadjuvant therapy plus surgery
or surgery alone. Two small observational studies have suggested
that postoperative HRQOL is not affected by addition of nCRT to
surgery, but these studies used different nCRT regimens and were
criticized because of the potential inﬂuence of selection bias and
lack of statistical power.17,18 The randomized design of our study
largely excludes selection bias, and the relatively large sample size
increases the power to detect small but clinically relevant differ-
ences. Hence, these results demonstrate more reliably that post-
operative HRQOL is not affected by nCRT, thereby conﬁrming the
results from these previous studies. These ﬁndings can help clinicians
and patients to make more properly informed treatment decisions,
especially patients who fear the negative effect of neoadjuvant treat-
ment. Besides the relatively low toxicity and the strong effect on survival
after nCRT plus surgery according to CROSS,9,10 the comparable effect
on postoperative HRQOL with surgery alone conﬁrms that the
beneﬁts of this effective regimen outweigh its harms. Nevertheless,
it should be noted that the application of nCRT delays surgery and
subsequent postoperative recovery by 2 to 3 months. This delay is
substantial, especially for patients who turn out to be nonsurvivors.
Furthermore, the long-term effects of adding nCRT to surgery on
HRQOL are largely unknown and need to be further explored.
Although it has been shown that nCRT containing cisplatin and
ﬂuorouracil with 66 Gy of concurrent radiotherapy signiﬁcantly
hampers long-term HRQOL, the CROSS regimen theoreti-
cally may have fewer negative effects because of the mild toxicity
of the applied chemotherapeutic agents and the relatively low
radiation dose.27
In line with our study, a profound deterioration in HRQOL
scores immediately after completion of nCRT has been described in
the phase II CROSS-I trial and other observational studies.17,18,28
Table 1. Baseline Characteristics of Patients With Potentially Curable
Esophageal or Esophagogastric Junction Cancer According to Treatment
Group
Characteristic
No. (%)
nCRT Plus Surgery
(n = 177)
Surgery Alone
(n = 186)
Age, years
Median 60 60
IQR 55-67 54-66
Male sex 134 (76) 151 (81)
Tumor type
Adenocarcinoma 134 (76) 140 (75)
Squamous cell carcinoma 40 (23) 42 (23)
Large-cell undifferentiated 3 (2) 4 (2)
Tumor location*
Esophagus
Proximal third 4 (2) 4 (2)
Middle third 24 (14) 23 (12)
Distal third 104 (59) 107 (58)
Esophagogastric junction 39 (22) 48 (26)
Missing data 6 (3) 4 (2)
Clinical T stage†
cT1 1 (1) 1 (1)
cT2 26 (15) 35 (19)
cT3 149 (84) 145 (78)
cT4‡ 0 1 (1)
Could not be determined§ 1 (1) 4 (2)
Clinical N stagek
N0 59 (33) 58 (31)
N1 115 (65) 118 (63)
Could not be determined§ 3 (2) 10 (5)
WHO performance status¶
0 144 (81) 161 (87)
1 33 (19) 25 (13)
NOTE. Percentages may not add up to 100 because of rounding.
Abbreviations: IQR, interquartile range; nCRT, neoadjuvant chemoradiotherapy.
*Tumor length and location were determined by means of endoscopy.
†Clinical T stage was assessed by means of endoscopic ultrasonography or
computed tomography and was classiﬁed according to the International Union
Against Cancer TNM classiﬁcation (sixth edition).26
‡One patient was originally staged as cT3, but this was revised to cT4 based on
central revision of all endoscopy reports.9
§This category included patients in whom the tumor could not be fully in-
vestigated by means of a transducer for endoscopic ultrasonography because of
stenosis caused by the tumor.
ǁClinical N stage was assessed by means of endoscopic ultrasonography,
computed tomography, or [18F]ﬂuorodeoxyglucose positron emission tomog-
raphy and was classiﬁed according to the International Union Against Cancer
TNM classiﬁcation (sixth edition).26
¶WHO performance status on a scale of 0 to 5, with lower numbers indicating
better performance status; 0 indicates fully active, and 1 unable to carry out
heavy physical work.
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This decline in all end points 1 week after completion of nCRT is
explained by persisting adverse effects of chemotherapy and ra-
diotherapy, such as anorexia, FA, esophagitis, and hematologic
toxicity. This emphasizes the need for sufﬁcient time between nCRT
and surgery, which allows patients to recover and reach more
optimal physical condition before surgery. Earlier studies have
suggested that postponement of surgery to at least 12 weeks after
nCRT does not jeopardize long-term oncologic outcome and even
tends to increase the pathologic complete response rate, which
might improve prognostication.29,30 Unfortunately, no HRQOL
Table 2. Patient QOL Questionnaire Completion
Status
Measurement Point
Baseline Post-nCRT
Postsurgery (months)
3 6 9 12
Eligible 363 177 342 308 285 260
nCRT + surgery 177 177 163 151 145 136
Surgery alone 186 179 157 140 124
Returned total (% of eligible) 235 (65) 104 (59) 228 (67) 210 (68) 185 (65) 166 (64)
nCRT + surgery 134 (76) 104 (59) 119 (73) 113 (75) 103 (71) 94 (69)
Surgery alone 101 (54) NA 109 (61) 97 (62) 82 (59) 72 (58)
Died 0 0 21 55 78 103
Too ill 0 24 38 27 36 32
Randomly missing/other 128* 49 76 71 64 62
Abbreviations: NA, not applicable; nCRT, neoadjuvant chemoradiotherapy; QOL, quality of life.
*Eighty nine missing because of administrative error.
Table 3. Mean Scores for All Domains in Two EORTC Questionnaires That Were Not Predeﬁned End Points According to Treatment Group
Measure
Measurement Point
Mean (SD)
Baseline Post-nCRT
Postsurgery (months)
3 6 9 12
Surgery
Alone nCRT
Surgery
Alone nCRT
Surgery
Alone nCRT
Surgery
Alone nCRT
Surgery
Alone nCRT
Surgery
Alone nCRT
QLQ-C30
Functional scales
Role 85 (22) 88 (24) NA 57 (29) 55 (32) 60 (30) 68 (29) 68 (30) 73 (26) 76 (28) 78 (24) 77 (27)
Emotional 71 (20) 71 (21) NA 74 (21) 75 (24) 78 (21) 76 (22) 80 (23) 80 (18) 82 (19) 77 (20) 83 (20)
Cognitive 89 (16) 93 (15) NA 84 (21) 82 (21) 82 (22) 85 (18) 85 (17) 84 (18) 86 (17) 84 (19) 87 (19)
Social 85 (20) 87 (20) NA 77 (24) 68 (27) 69 (28) 75 (25) 80 (21) 78 (25) 84 (22) 83 (23) 85 (23)
Symptom scores
Nausea and vomiting 12 (20) 8 (14) NA 22 (28) 21 (24) 19 (23) 13 (20) 21 (24) 12 (18) 13 (18) 11 (16) 12 (19)
Pain 14 (20) 14 (20) NA 31 (29) 23 (28) 17 (23) 21 (25) 17 (24) 15 (24) 13 (22) 17 (20) 11 (19)
Dyspnea 10 (20) 5 (12) NA 20 (26) 26 (27) 28 (29) 22 (27) 24 (26) 22 (26) 18 (23) 16 (22) 17 (24)
Insomnia 20 (28) 23 (26) NA 29 (31) 26 (31) 22 (30) 22 (26) 20 (28) 26 (30) 15 (23) 19 (26) 17 (26)
Loss of appetite 14 (24) 13 (25) NA 41 (36) 30 (33) 34 (33) 18 (27) 24 (33) 13 (25) 12 (20) 13 (22) 14 (24)
Constipation 6 (15) 8 (19) NA 24 (33) 13 (26) 9 (23) 10 (19) 6 (17) 9 (20) 6 (16) 10 (22) 9 (20)
Diarrhea 5 (12) 2 (10) NA 14 (26) 21 (27) 21 (28) 22 (26) 20 (25) 16 (22) 17 (23) 17 (21) 15 (23)
Financial worries 6 (17) 9 (20) NA 8 (19) 10 (20) 12 (24) 14 (24) 13 (21) 9 (18) 13 (20) 13 (24) 12 (22)
QLQ-OES24
Dysphagia 62 (34) 64 (35) NA 53 (32) 70 (31) 74 (28) 79 (29) 75 (30) 75 (33) 76 (30) 74 (34) 77 (29)
Deglutition 16 (23) 15 (24) NA 14 (20) 19 (23) 21 (23) 15 (24) 13 (21) 18 (26) 15 (21) 13 (20) 15 (23)
Swallowing of saliva 17 (30) 18 (31) NA 18 (29) 18 (31) 18 (30) 15 (29) 11 (26) 17 (30) 16 (29) 12 (22) 15 (27)
Aspiration 13 (23) 13 (24) NA 9 (19) 19 (25) 23 (26) 16 (25) 15 (23) 17 (25) 15 (21) 14 (23) 16 (23)
GI symptoms (24) 22 (19) 15 (15) NA 21 (19) 23 (21) 18 (18) 22 (19) 20 (18) 21 (21) 21 (20) 24 (23) 20 (21)
GI symptoms (18) 9 (19) 7 (16) NA 16 (23) 17 (26) 12 (20) 18 (23) 17 (22) 18 (24) 20 (24) 21 (25) 18 (24)
Pain 23 (24) 18 (21) NA 32 (25) 12 (16) 12 (19) 12 (18) 11 (13) 11 (17) 11 (19) 12 (19) 8 (13)
Dry mouth 14 (24) 9 (20) NA 25 (31) 19 (29) 21 (30) 13 (24) 21 (26) 16 (25) 20 (31) 18 (24) 16 (24)
Trouble with taste 10 (23) 7 (21) NA 37 (37) 24 (33) 24 (33) 13 (26) 14 (25) 13 (24) 11 (24) 13 (23) 9 (21)
Trouble with coughing 16 (22) 13 (21) NA 31 (31) 37 (34) 41 (35) 29 (29) 25 (30) 29 (29) 24 (27) 22 (24) 16 (20)
Trouble with speaking 6 (17) 4 (16) NA 6 (17) 19 (28) 18 (29) 11 (25) 11 (25) 13 (28) 11 (25) 14 (28) 11 (25)
Hair loss 0 (0) 0 (0) NA 24 (29) 8 (24) 23 (34) 24 (25) 18 (30) 29 (37) 26 (40) 19 (26) 15 (29)
NOTE. Scores are presented as mean. Standard deviations are shown between parentheses.
Abbreviations: EORTC, European Organisation for Research and Treatment of Cancer; NA, not applicable; nCRT, neoadjuvant chemoradiotherapy; QLQ-C30, Quality of
Life Questionnaire–Core 30; QLQ-OES24, Quality of Life Questionnaire–Oesophageal Cancer Module; SD, standard deviation.
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Fig 2. Mean scores with standard deviations for primary end points (A) physical functioning (PF) and (B) eating problems (EA) and secondary end points (C) global quality
of life (GQOL), (D) fatigue (FA), and (E) emotional problems (EM) according to treatment group. nCRT, neoadjuvant chemoradiotherapy.
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assessment was performed during nCRT or just before surgery. In
clinical practice, we have witnessed general improvements in pa-
tients’ condition in the period between nCRT and surgery. There-
fore, we recommend timing of surgery to be guided by patients’
condition, and we advocate that surgery should be postponed to up
to 12 weeks after completion of nCRT in case of persisting adverse
events or bad general condition. To further optimize the timing of
surgery, the course of HRQOL in the period between nCRT and
surgery should be monitored more carefully. On the basis of the
available literature and our clinical experience, it seems that HRQOL
substantially improves over a period of 6 to 12 weeks.17
Although some studies have suggested that the effect of
esophagectomy onHRQOL is restoredwithin 1 year postoperatively15
or can be attributed to only a small group of patients,31 most
studies have shown lasting and substantial negative effects.13,14,32
This is conﬁrmed by the results of our study, in which two of the
ﬁve end points (ie, PF and FA) did not return to baseline levels
during the ﬁrst year follow-up, and none of the end points
improved compared with baseline levels (for patients suffering
from esophageal cancer). These effects could only partly be explained
by recurrence of disease or death in the subsequent study period,
emphasizing the adverse effect of esophagectomy on HRQOL.
Cognitive behavioral therapy, which was not routinely offered in
our study, might be successful in treating patients with lasting FA.33
Furthermore, new treatment strategies, such as minimally invasive
esophagectomy and an active surveillance approach after nCRT
(instead of standard surgery), might improve HRQOL in these
patients.34,35
Limitations of this study include overall attrition and lower
response rates in the surgery-alone group than in the nCRT group.
Attrition is inevitable in HRQOL studies with severely ill patients.
Nevertheless, at each measurement point, pretreatment prognostic
parameters of patients who completed the questionnaires were
comparable between the two treatment groups, suggesting the
effect of attrition bias to be small. Lower response rates in the
surgery-alone group might be explained by primary surgery being
standard treatment during the performance of the trial. Conse-
quently, patients in the surgery-alone group could have been less
motivated to complete HRQOL questionnaires than patients in the
experimental nCRT group. Another possible explanation is the
increasing rate of recurrence being more common in the surgery-
alone group.
Because of the relatively low number of older patients (pa-
tients age $ 76 years were excluded from the trial) and patients
with poorer performance status (patients withWHO. 2 were also
excluded), results from this study cannot be generalized to these
speciﬁc categories of vulnerable patients. The effect of this treat-
ment regimen on HRQOL will need to be tested for these sub-
groups of patients in future studies.
Furthermore, it has been pointed out previously that patients
who receive neoadjuvant treatment may report better recovery
from surgery, as a result of adjustments to toxicity as experienced
during neoadjuvant treatment leading to a re-evaluation of internal
standards (ie, response shift). In our study, it was not possible to
correct for this potential effect.17
Finally, although formally validated, sensitivity of HRQOL
questionnaires remains uncertain, and these questionnaires might
be too crude to detect small but clinically relevant differences. To
optimize precision, both generic and disease-speciﬁc question-
naires were used, and together with the large sample size of the
current trial, we expect sensitivity to be relatively high compared
with that of earlier studies on this topic. Of note, the QLQ-OES24
questionnaire has been reﬁned into the QLQ-OES18, with revision
of the hypothesized scales and the removal of two single items. We
do not believe this invalidates the results of our study, because the
EA scale was retained in its original form. The EM scale showed
modest to high correlations within all validation analyses but was
deleted because of overlap with the QLQ-C30 questionnaire.21
In conclusion, although HRQOL declined immediately after
nCRT, no effect of nCRT according to CROSS was apparent on
postoperative short-term HRQOL compared with surgery alone.
In addition to the earlier described improvement in long-term
overall and disease-free survival, these results support the view that
nCRT according to this effective regimen should be regarded as
a standard of care for patients with locally advanced resectable
esophageal or esophagogastric junctional cancer.
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Appendix
Trial Design
Details of this multicenter, randomized trial, have been reported previously.9,10,19 Brieﬂy, patients with locally advanced
(clinical stage T1N1M0 or T2–3N0–1M0 according to the 6th edition of the TNM cancer staging)26, histologically proven
squamous cell carcinoma (SCC), adenocarcinoma (AC) or large-cell undifferentiated carcinoma of the esophagus or esoph-
agogastric junction (EGJ) were eligible for inclusion. Eligible patients were between 18 and 75 years of age; had adequate pul-
monary, hematological, hepatic and renal function; and aWHO performance score of 2 or better. The study protocol was approved
by the institutional review boards and all patients provided written informed consent.
Randomization
Patients were randomized 1:1 to each treatment group, with random permuted block sizes of 4 or 6. All patients were stratiﬁed
according to treatment center, WHO performance score, histological tumor type and clinical lymph node status.
Procedures
Patients assigned to the nCRT group received carboplatin (AUC 2 mg/mL per min) and paclitaxel (50 mg/m2 of body-surface
area) intravenously for ﬁve cycles on days 1, 8, 15, 22, and 29. Concurrent radiation therapy of 41.4 Gy was given in 23 fractions of
1.8 Gy, 5 days per week. Patients in the surgery alone group received surgery as soon as possible, whereas those in the nCRT plus
surgery group preferably had surgery 4 to 6 weeks after completion of nCRT. For carcinomas at or above the level of the carina,
a transthoracic esophagectomy with two-ﬁeld lymphadenectomy was performed. For carcinomas located well below the carina,
either a transthoracic esophagectomy with two-ﬁeld lymphadenectomy or a transhiatal esophagectomy with upper abdominal and
lower mediastinal lymphadenectomy was performed, depending on patient characteristics and local preferences. For carcinomas
involving the esophagogastric junction, a transhiatal esophagectomy was preferred. During the ﬁrst year after completion of
treatment, follow-up took place every 3 months. In the second year, patients were followed every 6 months and annually thereafter
until 5 years after completion of treatment. Additional visits were scheduled if complaints arose before the next visit.9,10
Table A1. Mixed Modeling Analysis Including Randomized Grouping for Longitudinal Effects on Physical Functioning
Parameter Cohen’s d* P 95% CI
Baseline scores for nCRT group 0.56 , .001 0.47 to 0.65
Difference for surgery alone 20.04 .598 20.18 to 0.10
Comparison with baseline
1 week post-nCRT 20.93 , .001 21.12 to 20.74
3 months postsurgery for nCRT group 21.09 , .001 21.29 to 20.90
Difference for surgery alone 0.21 .157 20.08 to 0.49
6 months postsurgery for nCRT group 20.70 , .001 20.89 to 20.52
Difference for surgery alone 0.01 .968 20.27 to 0.28
9 months postsurgery for nCRT group 20.53 , .001 20.72 to 20.35
Difference for surgery alone 20.15 .287 20.43 to 0.13
12 months postsurgery for nCRT group 20.51 , .001 20.69 to 20.32
Difference for surgery alone 20.05 .717 20.34 to 0.23
Comparison with previous measurement
3 months postsurgery for nCRT group 20.16 .164 20.38 to 0.07
6 months postsurgery for nCRT group 0.39 , .001 0.24 to 0.54
Difference for surgery alone 20.20 .079 20.43 to 0.02
9 months postsurgery for nCRT group 0.17 .022 0.02 to 0.32
Difference for surgery alone 20.16 .159 20.38 to 0.06
12 months postsurgery for nCRT group 0.03 .730 20.14 to 0.19
Difference for surgery alone 0.10 .430 20.15 to 0.35
Abbreviation: nCRT, neoadjuvant chemoradiotherapy.
*Cohen’s d effect sizes were derived from the beta estimates in the mixed-modeling procedure through standardization of both outcome and predictor variables.
Differences between the two treatment groups at baseline measurement and differences in change between measurements are referred to as difference for surgery
alone.
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Table A2. Mixed Modeling Analysis Including Randomized Grouping for Longitudinal Effects on Global Health Status
Parameter Cohen’s d* P 95% CI
Baseline scores for nCRT group 0.22 .004 0.07 to 0.37
Difference for surgery alone 20.07 .533 20.30 to 0.16
Comparison with baseline
1 week post-nCRT 20.84 , .001 21.08 to 20.60
3 months postsurgery for nCRT group 20.52 , .001 20.72 to 20.31
Difference for surgery alone 0.11 .467 20.19 to 0.42
6 months postsurgery for nCRT group 20.21 .058 20.42 to 0.01
Difference for surgery alone 20.04 .801 20.36 to 0.28
9 months postsurgery for nCRT group 20.06 .574 20.29 to 0.16
Difference for surgery alone 20.05 .776 20.39 to 0.29
12 months postsurgery for nCRT group 20.04 .729 20.27 to 0.19
Difference for surgery alone 0.05 .799 20.31 to 0.40
Comparison with previous measurement
3 months postsurgery for nCRT group 0.33 .008 0.09 to 0.57
6 months postsurgery for nCRT group 0.31 .001 0.13 to 0.49
Difference for surgery alone 20.16 .255 20.42 to 0.11
9 months postsurgery for nCRT group 0.14 .145 20.05 to 0.34
Difference for surgery alone 20.01 .958 20.30 to 0.28
12 months postsurgery for nCRT group 0.02 .792 20.15 to 0.20
Difference for surgery alone 0.09 .491 20.18 to 0.37
Abbreviation: nCRT, neoadjuvant chemoradiotherapy.
*Cohen’s d effect sizes were derived from the beta estimates in the mixed-modeling procedure through standardization of both outcome and predictor variables.
Differences between the two treatment groups at baseline measurement and differences in change between measurements are referred to as difference for surgery
alone.
Table A3. Mixed Modeling Analysis Including Randomized Grouping for Longitudinal Effects on Fatigue
Parameter Cohen’s d* P 95% CI
Baseline scores for nCRT group 20.63 , .001 20.76 to 20.49
Difference for surgery alone 0.08 .421 20.12 to 0.29
Comparison with baseline
1 week post-nCRT 1.45 , .001 1.23 to 1.67
3 months postsurgery for nCRT group 1.12 , .001 0.91 to 1.32
Difference for surgery alone 20.23 .137 20.53 to 0.07
6 months postsurgery for nCRT group 0.74 , .001 0.54 to 0.93
Difference for surgery alone 20.14 .331 20.44 to 0.15
9 months postsurgery for nCRT group 0.53 , .001 0.34 to 0.72
Difference for surgery alone 0.05 .754 20.25 to 0.34
12 months postsurgery for nCRT group 0.49 , .001 0.31 to 0.68
Difference for surgery alone 0.05 .723 20.23 to 0.33
Comparison with previous measurement
3 months postsurgery for nCRT group 20.33 .002 20.54 to 20.12
6 months postsurgery for nCRT group 20.38 , .001 20.54 to 20.22
Difference for surgery alone 0.08 .487 20.15 to 0.32
9 months postsurgery for nCRT group 20.21 .010 20.37 to 20.05
Difference for surgery alone 0.19 .119 20.05 to 0.43
12 months postsurgery for nCRT group 20.03 .656 20.19 to 0.12
Difference for surgery alone 0.00 .970 20.23 to 0.24
Abbreviation: nCRT, neoadjuvant chemoradiotherapy.
*Cohen’s d effect sizes were derived from the beta estimates in the mixed-modeling procedure through standardization of both outcome and predictor variables.
Differences between the two treatment groups at baseline measurement and differences in change between measurements are referred to as difference for surgery
alone.
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Table A4. Mixed Modeling Analysis Including Randomized Grouping for Longitudinal Effects on Emotional Problems
Parameter Cohen’s d* P 95% CI
Baseline scores for nCRT group 20.09 .262 20.26 to 0.07
Difference for surgery alone 0.18 .159 20.07 to 0.43
Comparison with baseline
1 week post-nCRT 0.32 .001 0.14 to 0.50
3 months postsurgery for nCRT group 0.40 , .001 0.19 to 0.61
Difference for surgery alone 20.15 .346 20.46 to 0.16
6 months postsurgery for nCRT group 0.14 .215 20.08 to 0.36
Difference for surgery alone 20.15 .362 20.48 to 0.18
9 months postsurgery for nCRT group 20.14 .218 20.37 to 0.09
Difference for surgery alone 0.00 .992 20.35 to 0.35
12 months postsurgery for nCRT group 20.14 .210 20.36 to 0.08
Difference for surgery alone 20.06 .712 20.40 to 0.28
Comparison with previous measurement
3 months postsurgery for nCRT group 0.08 .459 20.13 to 0.28
6 months postsurgery for nCRT group 20.26 .006 20.45 to 20.07
Difference for surgery alone 0.00 .989 20.28 to 0.27
9 months postsurgery for nCRT group 20.28 .003 20.47 to 20.10
Difference for surgery alone 0.15 .295 20.13 to 0.43
12 months postsurgery for nCRT group 0.00 .982 20.19 to 0.19
Difference for surgery alone 20.06 .675 20.36 to 0.23
Abbreviation: nCRT, neoadjuvant chemoradiotherapy.
*Cohen’s d effect sizes were derived from the beta estimates in the mixed-modeling procedure through standardization of both outcome and predictor variables.
Differences between the two treatment groups at baseline measurement and differences in change between measurements are referred to as difference for surgery
alone.
Table A5. Mixed Modeling Analysis Including Randomized Grouping for Longitudinal Effects on Eating Problems
Parameter Cohen’s d* P 95% CI
Baseline scores for nCRT group 20.10 .294 20.28 to 0.09
Difference for surgery alone 0.21 .136 20.07 to 0.49
Comparison with baseline
1 week post-nCRT 0.47 .001 0.21 to 0.72
3 months postsurgery for nCRT group 0.43 .001 0.19 to 0.68
Difference for surgery alone 20.25 .177 20.61 to 0.11
6 months postsurgery for nCRT group 0.07 .582 20.17 to 0.30
Difference for surgery alone 20.15 .403 20.50 to 0.20
9 months postsurgery for nCRT group 20.13 .267 20.37 to 0.10
Difference for surgery alone 20.19 .283 0.55 to 0.16
12 months postsurgery for nCRT group 20.21 .086 20.45 to 0.03
Difference for surgery alone 20.05 .774 20.42 to 0.31
Comparison with previous measurement
3 months postsurgery for nCRT group 20.03 .816 20.30 to 0.23
6 months postsurgery for nCRT group 20.37 , .001 20.53 to 20.21
Difference for surgery alone 0.10 .422 20.14 to 0.33
9 months postsurgery for nCRT group 20.20 .022 20.37 to 20.03
Difference for surgery alone 20.04 .741 20.30 to 0.21
12 months postsurgery for nCRT group 20.08 .280 20.22 to 0.07
Difference for surgery alone 0.14 .212 20.08 to 0.36
Abbreviation: nCRT, neoadjuvant chemoradiotherapy.
*Cohen’s d effect sizes were derived from the beta estimates in the mixed-modeling procedure through standardization of both outcome and predictor variables.
Differences between the two treatment groups at baseline measurement and differences in change between measurements are referred to as difference for surgery
alone.
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